Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

 Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices               Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas, April 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that through its collaboration agreement with a large networ ...